NCT03458247View on ClinicalTrials.gov

Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 22, 2018

Primary Completion Date

April 29, 2021

Study Completion Date

December 27, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone acetate standard dose

1000 mg/day

DRUG

Abiraterone acetate escalated dose

2000 mg/day

Trial Locations (1)

75014

Department of Medical Oncology, Cochin Hospital, Paris

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03458247 - Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer | Biotech Hunter | Biotech Hunter